Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
For the full year, sales was INR 504.22 million compared to INR 521.34 million a year ago. Revenue was INR 508.73 million compared to INR 527.55 million a year ago. Net loss was INR 197.28 million compared to INR 246.92 million a year ago. Basic loss per share from continuing operations was INR 9.16 compared to INR 11.3 a year ago. Diluted loss per share from continuing operations was INR 9.16 compared to INR 11.3 a year ago.